AR069334A1 - Inhibidores de la replicacion del virus de inmunodeficiencia humana - Google Patents
Inhibidores de la replicacion del virus de inmunodeficiencia humanaInfo
- Publication number
- AR069334A1 AR069334A1 ARP080104989A ARP080104989A AR069334A1 AR 069334 A1 AR069334 A1 AR 069334A1 AR P080104989 A ARP080104989 A AR P080104989A AR P080104989 A ARP080104989 A AR P080104989A AR 069334 A1 AR069334 A1 AR 069334A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- het
- cycloalkyl
- aryl
- independently selected
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000010076 replication Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 29
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000002947 alkylene group Chemical group 0.000 abstract 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001118 alkylidene group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- -1 C3- cycloalkyl 7 Chemical group 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000464 thioxo group Chemical group S=* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los compuestos de formula (1), composiciones farmacéuticas, usos para el tratamiento de infeccion por VIH. Reivindicacion 1: Un isomero, racemato, enantiomero o diastereoisomero de un compuesto caracterizado porque tiene la formula (1): en la que --------- representa un enlace sencillo o doble enlace; X es S o CR5; Y es S o CR7; en la que uno de X o Y es S; R2, R5, R6 y R7 se selecciona cada uno independientemente de: a) halogeno; b) R8, -C(=O)-R8, -C(=O)-O-R8, -O-R8, -S-R8, SO-R8, -SO2-R8, -alquilen C1-6-R8, -alquilen C1-6-C(=O)-R8, -alquilen C1-6-C(=O)-O-R8, -alquilen C1-6-SO-R8 o -alquilen C1-6-SO2-R8, -alquilen C1-6-O-R8 o -alquilen C1-6-S-R8; en los que R8 en cada caso se selecciona independientemente de H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, cicloalquilo C3-7, arilo y Het; y en el que cada uno del arilo y Het está opcionalmente sustituido con 1 a 3 sustituyentes, cada uno independientemente seleccionado de i) halogeno, oxo, tioxo, alquenilo C2-6, haloalquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6-, -OH, -O-alquilo C1-6, -O-haloalquilo C1-6), -SH, -S-alquilo C1-6, -SO-alquilo C1-6, -SO2-alquilo C1-6, -NH2, -NH-alquilo C1-6 y -N(alquilo C1-6)2; ii) alquilo C1-6 opcionalmente sustituido con -OH, -O-haloalquilo C1-6 o -O-alquilo C1-6; y iii) arilo o Het, en el que cada uno del arilo y Het está opcionalmente sustituido con halogeno o alquilo C1-6; y c) -N(R9)R10, -C(=O)N(R9)R10, -O-C(=O)N(R9)R10, -SO2-N(R9)R10, -alquilen C1-6-N(R9)R10, -alquilen C1-6-C(=O)-N(R9)R10, -alquilen C1-6)-O-C(=O)-N(R9)R10 o -alquilen C1-6-SO2-N(R9)R10 en los que R9 en cada caso se selecciona independientemente de H, alquilo C1-6 y cicloalquilo C3-7; y R10 en cada caso se selecciona independientemente de R8, -alquilen C1-6-R8, -SO2-R8, -C(=O)-R8, -C(=O)OR8 y -C(=O)N(R9)R8; en donde R8 y R9 son como se ha definido antes; R3 es alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquil C3-7-alquilo C1-6), aril-alquilo C1-6, Het-alquilo C1-6 o -W-R31, y el enlace c es un enlace sencillo; o R3 es alquilideno C1-6 y el enlace c es un doble enlace: en el que W es O o S y R31 es alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo, cicloalquil C3-7-alquilo C1-6, aril-alquilo C1-6 o Het-alquilo C1-6; en los que cada uno de alquilideno C1-6, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquil C3-7-alquilo C1-6, aril-alquilo C1-6, Het-alquilo C1-6 y -W-R31 está opcionalmente sustituido con 1 a 3 sustituyentes, cada uno independientemente seleccionado de alquilo C1-6, halogeno, ciano, oxo y -O-alquilo C1-6; R4 es arilo o Het, en el que cada uno de los arilo y Het está opcionalmente sustituido con 1 a 5 sustituyentes cada uno independientemente seleccionado de halogeno, alquilo C1-6, alquenilo C2-6, haloalquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6-, -OH, -O-alquilo C1-6, -SH, -S-alquilo C1-6, -NH2, -NH-alquilo C1-6 y -N(alquilo C1-6)2 en los que el alquilo C1-6 está opcionalmente sustituido con hidroxi, -O-alquilo C1-6, ciano u oxo; y en el que Het es un heterociclo de 4 a 7 miembros saturado, insaturado o aromático que tiene de 1 a 4 heteroátomos, cada uno independientemente seleccionado de O, N y S o un heteropoliciclo de 7 a 14 miembros, saturado, insaturado o aromático que tiene, siempre que sea posible, de 1 a 5 heteroátomos, cada uno independientemente seleccionado de O, N y S; en el que cada heteroátomo de N, independientemente y cuando sea posible, puede existir en un estado oxidado de modo que además está unido a un átomo de oxígeno para formar un grupo N-oxido y en el que cada heteroátomo de S, independientemente y cuando sea posible, existe en un estado oxidado de modo que está además unido a uno o dos átomos de oxígeno para formar los grupos SO o SO2 o una de sus sales o ésteres.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98834207P | 2007-11-15 | 2007-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069334A1 true AR069334A1 (es) | 2010-01-13 |
Family
ID=40638277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104989A AR069334A1 (es) | 2007-11-15 | 2008-11-14 | Inhibidores de la replicacion del virus de inmunodeficiencia humana |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7956068B2 (es) |
| EP (2) | EP2220095B1 (es) |
| JP (1) | JP5269085B2 (es) |
| KR (1) | KR20100108337A (es) |
| CN (1) | CN102124011A (es) |
| AR (1) | AR069334A1 (es) |
| AU (1) | AU2008323561B2 (es) |
| BR (1) | BRPI0819328A8 (es) |
| CA (1) | CA2705312C (es) |
| CL (1) | CL2008003405A1 (es) |
| ES (1) | ES2402322T3 (es) |
| IL (1) | IL205746A0 (es) |
| MX (1) | MX2010005292A (es) |
| NZ (1) | NZ585297A (es) |
| RU (1) | RU2503679C2 (es) |
| TW (1) | TW200920363A (es) |
| WO (1) | WO2009062288A1 (es) |
| ZA (1) | ZA201003305B (es) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1831216A2 (en) * | 2004-12-23 | 2007-09-12 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| NZ604716A (en) | 2010-07-02 | 2014-12-24 | Gilead Sciences Inc | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| BR112013000043A2 (pt) | 2010-07-02 | 2019-09-24 | Gilead Sciences Inc | derivados de ácido naft-2-ilacético para tratar aids |
| US8633200B2 (en) | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| EP2640705A2 (en) | 2010-11-15 | 2013-09-25 | Katholieke Universiteit Leuven | Novel antiviral compounds |
| CA2817896A1 (en) * | 2010-11-15 | 2012-05-24 | Viiv Healthcare Uk Limited | Inhibitors of hiv replication |
| WO2012138670A1 (en) * | 2011-04-04 | 2012-10-11 | Gilead Sciences, Inc. | Process for the preparation of an hiv integrase inhibitor |
| EP2508511A1 (en) | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| ES2742261T3 (es) * | 2011-04-15 | 2020-02-13 | Hivih | Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos |
| SG194512A1 (en) * | 2011-04-21 | 2013-12-30 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
| JP6055468B2 (ja) * | 2011-07-15 | 2016-12-27 | ヴィーブ ヘルスケア ユーケー リミテッド | アザインドール化合物及びｈｉｖを治療するための方法 |
| US8791108B2 (en) | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2013062028A1 (ja) | 2011-10-25 | 2013-05-02 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害剤 |
| EP2781519B1 (en) * | 2011-11-15 | 2019-10-30 | ST Pharm Co., Ltd. | Novel antiviral pyrrolopyridine derivative and a production method for same |
| WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
| US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
| US8629276B2 (en) | 2012-02-15 | 2014-01-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9034882B2 (en) * | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| ES2571479T3 (es) | 2012-04-20 | 2016-05-25 | Gilead Sciences Inc | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
| JP6129962B2 (ja) * | 2012-07-12 | 2017-05-17 | ヴィーブ ヘルスケア ユーケー リミテッド | 化合物及びｈｉｖを治療するための方法 |
| US8906929B2 (en) * | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| EP2716639A1 (en) | 2012-10-05 | 2014-04-09 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| EP2716632A1 (en) | 2012-10-05 | 2014-04-09 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| EP2719685A1 (en) | 2012-10-11 | 2014-04-16 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| TW201441197A (zh) | 2013-01-31 | 2014-11-01 | Shionogi & Co | Ｈｉｖ複製抑制劑 |
| WO2014164467A1 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2014164428A1 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2014164409A1 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9527842B2 (en) | 2013-03-14 | 2016-12-27 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US9540393B2 (en) | 2013-03-14 | 2017-01-10 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| CA2910514C (en) | 2013-06-11 | 2018-05-15 | Latvian Institute Of Organic Synthesis | Thieno[2,3-.beta.]pyridines as multidrug resistance modulators |
| EP2821082A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use |
| EP2821104A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| EP3105236B1 (en) | 2014-02-12 | 2017-10-18 | ViiV Healthcare UK (No.5) Limited | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| US9409922B2 (en) | 2014-02-18 | 2016-08-09 | Bristol-Myers Squibb Company | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
| WO2015126758A1 (en) | 2014-02-18 | 2015-08-27 | Bristol-Myers Squibb Company | Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| WO2015126743A1 (en) | 2014-02-18 | 2015-08-27 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| EP3107913B1 (en) | 2014-02-19 | 2018-07-04 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US9273067B2 (en) | 2014-02-19 | 2016-03-01 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| EP3116880B1 (en) | 2014-02-20 | 2018-03-21 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication |
| US9193720B2 (en) | 2014-02-20 | 2015-11-24 | Bristol-Myers Squibb Company | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2015174511A1 (ja) | 2014-05-16 | 2015-11-19 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害作用を有する３環性複素環誘導体 |
| WO2016194806A1 (ja) | 2015-05-29 | 2016-12-08 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害作用を有する含窒素３環性誘導体 |
| US20180170903A1 (en) | 2015-07-06 | 2018-06-21 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| CA2991268A1 (en) | 2015-07-08 | 2017-01-12 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US20180147196A1 (en) | 2015-07-09 | 2018-05-31 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US20180170904A1 (en) | 2015-07-09 | 2018-06-21 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| EP3331868A1 (en) | 2015-08-07 | 2018-06-13 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| BR112018002681A2 (pt) | 2015-08-10 | 2019-04-24 | Viiv Healthcare Uk No 5 Ltd | ?composto, composição, e, método para tratamento de infecção por hiv? |
| AR105653A1 (es) | 2015-08-11 | 2017-10-25 | VIIV HEALTHCARE UK (Nº 5) LTD | Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana |
| AU2016305339A1 (en) | 2015-08-12 | 2018-03-01 | VIIV Healthcare UK (No.5) Limited | 5-(n-fused tricyclic Aryl tetrahydroisoquinolin-6-yl) pyridin-3- yl acetic acid derivatives as inhibitors of Human Immunodeficiency Virus replication |
| TW201718537A (zh) | 2015-08-12 | 2017-06-01 | Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 | 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物 |
| AU2016306088A1 (en) | 2015-08-12 | 2018-03-08 | VIIV Healthcare UK (No.5) Limited | 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| CA2995790A1 (en) | 2015-08-20 | 2017-02-23 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| EP3455217A1 (en) | 2016-05-11 | 2019-03-20 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| EP3455215A1 (en) | 2016-05-11 | 2019-03-20 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| EP3455214A1 (en) | 2016-05-11 | 2019-03-20 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US20200055839A1 (en) | 2017-01-03 | 2020-02-20 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| JP2020503352A (ja) | 2017-01-03 | 2020-01-30 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
| WO2019244066A2 (en) | 2018-06-19 | 2019-12-26 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2020003093A1 (en) | 2018-06-25 | 2020-01-02 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US20220056043A1 (en) * | 2019-02-19 | 2022-02-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof |
| CA3133100A1 (en) | 2019-03-19 | 2020-09-24 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic aza-benzothiophene and aza-benzofuran compounds |
| JP2023528822A (ja) | 2020-05-29 | 2023-07-06 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 駆虫性複素環式化合物 |
| WO2023073641A1 (en) | 2021-11-01 | 2023-05-04 | Boehringer Ingelheim Vetmedica Gmbh | Anthelmintic pyrrolopyridazine compounds |
| CN114436879A (zh) * | 2022-01-14 | 2022-05-06 | 海南三帝制药有限公司 | 一种盐酸三甲卡因的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8804448D0 (en) * | 1988-02-25 | 1988-03-23 | Smithkline Beckman Intercredit | Compounds |
| AU2436792A (en) * | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| ATE225351T1 (de) * | 1994-11-08 | 2002-10-15 | Takeda Chemical Industries Ltd | Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel |
| US5620997A (en) * | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| FR2761687B1 (fr) * | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
| EP1028964A1 (en) * | 1997-11-11 | 2000-08-23 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| FR2819507B1 (fr) * | 2001-01-17 | 2007-09-28 | Inst Rech Developpement Ird | Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus |
| EP2335700A1 (en) * | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| FR2839646B1 (fr) * | 2002-05-17 | 2008-04-11 | Bioalliance Pharma | Utilisation de derives de quinoleine a effet anti-integrase et ses applications |
| EP1541558B1 (en) * | 2002-08-13 | 2008-08-13 | Shionogi & Co., Ltd. | Heterocyclic compounds having hiv integrase inhibitory activity |
| US20060094755A1 (en) * | 2004-10-28 | 2006-05-04 | Bioflexis, Llc | Novel quinoline-based metal chelators as antiviral agents |
| EP1866313A1 (en) | 2005-03-31 | 2007-12-19 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Hiv integrase inhibitors |
| ES2567197T3 (es) | 2005-04-28 | 2016-04-20 | Viiv Healthcare Company | Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH |
| AU2006299042B8 (en) | 2005-10-04 | 2011-09-15 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | HIV integrase inhibitors |
| AU2006307101A1 (en) * | 2005-10-27 | 2007-05-03 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase |
| US7939545B2 (en) * | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
-
2008
- 2008-11-03 BR BRPI0819328A patent/BRPI0819328A8/pt not_active IP Right Cessation
- 2008-11-03 JP JP2010533394A patent/JP5269085B2/ja active Active
- 2008-11-03 EP EP08850892A patent/EP2220095B1/en active Active
- 2008-11-03 KR KR1020107013084A patent/KR20100108337A/ko not_active Application Discontinuation
- 2008-11-03 NZ NZ585297A patent/NZ585297A/en not_active IP Right Cessation
- 2008-11-03 WO PCT/CA2008/001935 patent/WO2009062288A1/en active Application Filing
- 2008-11-03 US US12/743,143 patent/US7956068B2/en active Active
- 2008-11-03 AU AU2008323561A patent/AU2008323561B2/en not_active Ceased
- 2008-11-03 CN CN2008801247470A patent/CN102124011A/zh active Pending
- 2008-11-03 MX MX2010005292A patent/MX2010005292A/es active IP Right Grant
- 2008-11-03 RU RU2010123989/04A patent/RU2503679C2/ru not_active IP Right Cessation
- 2008-11-03 CA CA2705312A patent/CA2705312C/en not_active Expired - Fee Related
- 2008-11-03 ES ES08850892T patent/ES2402322T3/es active Active
- 2008-11-03 EP EP12199561A patent/EP2574610A1/en not_active Withdrawn
- 2008-11-14 AR ARP080104989A patent/AR069334A1/es not_active Application Discontinuation
- 2008-11-14 TW TW097144270A patent/TW200920363A/zh unknown
- 2008-11-14 CL CL2008003405A patent/CL2008003405A1/es unknown
-
2010
- 2010-05-11 ZA ZA2010/03305A patent/ZA201003305B/en unknown
- 2010-05-13 IL IL205746A patent/IL205746A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201003305B (en) | 2011-03-30 |
| EP2220095A1 (en) | 2010-08-25 |
| WO2009062288A1 (en) | 2009-05-22 |
| EP2220095A4 (en) | 2011-01-26 |
| US20100305115A1 (en) | 2010-12-02 |
| CL2008003405A1 (es) | 2010-02-12 |
| MX2010005292A (es) | 2010-07-05 |
| ES2402322T3 (es) | 2013-04-30 |
| EP2574610A1 (en) | 2013-04-03 |
| AU2008323561B2 (en) | 2013-07-18 |
| CA2705312C (en) | 2013-06-25 |
| IL205746A0 (en) | 2010-11-30 |
| KR20100108337A (ko) | 2010-10-06 |
| AU2008323561A1 (en) | 2009-05-22 |
| EP2220095B1 (en) | 2013-01-02 |
| BRPI0819328A8 (pt) | 2016-02-10 |
| CA2705312A1 (en) | 2009-05-22 |
| JP5269085B2 (ja) | 2013-08-21 |
| NZ585297A (en) | 2012-06-29 |
| US7956068B2 (en) | 2011-06-07 |
| TW200920363A (en) | 2009-05-16 |
| BRPI0819328A2 (pt) | 2015-05-12 |
| CN102124011A (zh) | 2011-07-13 |
| RU2010123989A (ru) | 2011-12-20 |
| JP2011503117A (ja) | 2011-01-27 |
| RU2503679C2 (ru) | 2014-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069334A1 (es) | Inhibidores de la replicacion del virus de inmunodeficiencia humana | |
| AR069544A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana y composiciones farmaceuticas que los contienen | |
| AR069832A1 (es) | Inhibidores de la polimerasa virica | |
| AR060949A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| AR073659A1 (es) | Compuetsos inhibidores de la hepatitis c | |
| AR069335A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| AR049399A1 (es) | Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos | |
| AR100691A1 (es) | Esteroides neuroactivos, composiciones, y usos de los mismos | |
| AR101600A1 (es) | COMPUESTOS DE SPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2-p53 | |
| PE20180044A1 (es) | Compuestos novedosos | |
| AR059036A1 (es) | Compuestos para el tratamiento de trastornos inflamatorios | |
| AR090760A1 (es) | Compuestos de benzotiazol y su uso contra el virus de hiv | |
| AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
| AR047706A1 (es) | Inhibidores de polimerasa viral | |
| AR078622A1 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y sus usos | |
| AR050430A1 (es) | Analogos de dipeptidos inhibidores de la hepatitis c | |
| AR079553A1 (es) | Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros. | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| AR062423A1 (es) | Inhibidores de la polimerasa virica | |
| AR071376A1 (es) | Dihidropirazolonas sustituidas y su uso | |
| AR094876A1 (es) | Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo | |
| AR060605A1 (es) | Derivados de diazepano como antagonistas del receptor ccr2 | |
| AR071541A1 (es) | Inhibidores de la polimerasa virica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |